Navigation Links
Novel experimental agent is highly active in CLL patients, interim study shows
Date:12/11/2011

COLUMBUS, Ohio An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) is available to discuss the findings that were presented today (12/13) at the 53rd Annual Meeting of the American Society of Hematology in San Diego.

Study co-leader Dr. Susan O'Brien of The University of Texas M.D. Anderson Cancer Center reported the analysis, which involves 61 patients who have relapsed and whose cancer no longer responds to standard CLL therapy. Of these patients, 27 received a drug dose of 420 milligrams (mg) and 34 received a drug dose of 840 mg.

This study found that 70 percent of patients in the 420-mg group had either a complete or partial remission to treatment after 10 months of follow-up.

"These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions the remissions last months on end with acceptable toxicity in relapsed and refractory CLL," Byrd says. "These responses last for many months in part because patients are willing to remain on the drug since the side effects are very tolerable," he notes.

Complete remission means there is no detectable CLL anywhere in the body; partial remission means that the individual's disease volume has decreased 50 percent or more in a sustained manner.

Patients enrolled in this cohort of the ongoing phase II clinical trial are individuals with relapsed CLL, all of whom had two or more earlier treatments followed by recurrent disease.

"Usually patients with highly resistant and refractory CLL would have progressed and possibly died by this time, but 82 percent remain on PCI-32765 and continue to improve." Byrd says.
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story ... is the creation of published author, Larry R. Sherman, a retired chemistry professor from ... religion, as well as four novels. , Though the book opens in 1947, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty ... neglect, and the struggles faced while hoping for a better life. “Without Love’s ... Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Glimpses Of Light”: is a ... “Glimpses Of Light” is the creation of published author, J.M. Shepherd, a writer, teacher, ... answers to life’s perplexing mysteries. , Shepherd shares, “Love is one of the least ...
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a best-in-class ... Fatigue . , As the stress of modern life continually makes more demands on ... use of artificial stimulants can trap people in vicious high/low cycles and can also ...
(Date:8/22/2017)... Indiana (PRWEB) , ... August 22, 2017 , ... Although ... Fourth of July, many communities have begun providing weekend displays, and numerous households celebrate ... most humans, they can be downright terrifying for pets. , Kris Zambo, owner ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital ... environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new ... robot that uses UVC light energy to kill deadly pathogens such as C. diff ... Tru-D SmartUVC ... Tru-D in action in a ...
(Date:7/31/2017)... July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... Michigan by Crain,s Detroit Business . ... public companies by three-year revenue growth. This year,s edition measures ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... an incredible triumph," said Phil Hagerman , CEO and ...
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
Breaking Medicine Technology: